Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$10.72 USD
-0.03 (-0.28%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $10.69 -0.03 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CATX 10.72 -0.03(-0.28%)
Will CATX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CATX
Buy Rating Maintained for Perspective Therapeutics Amidst Positive Long-Term Growth Prospects and Upcoming Clinical Catalysts
Wall Street Analysts Are Bullish on Top Healthcare Picks
Perspective Therapeutics price target raised by $17 at Oppenheimer, here's why
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), AbbVie (ABBV)